================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 3, 2009
ONCOLOGIX TECH, INC.
---------------------------------------------------------
(Name of Small Business Issuer as Specified in Its Charter)
0-15482
----------------------
(Commission File Number)
Nevada 86-1006416
------------------------------ -----------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
P.O. Box 8832
Grand Rapids, MI 49518-8832
--------------------------------------
(Address of principal executive offices)
(616) 977-9933
-------------------------
(Issuer's telephone number)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of the close of business on April 3, 2009, Ms Judy Lindstrom
and Steven Kurtzman, MD, resigned as directors of the Registrant and Ms
Lindstrom also resigned as President and Chief Officer. Both Ms Lindstrom and
Dr. Kurtzman continue as Directors of Oncologix Corporation, the Registrant's
subsidiary, and Ms Lindstrom continues as President and Chief Executive Officer
of Oncologix Corporation. Effective as of the same time, Mr. Anthony Silverman
was elected as a Director and as President and Chief Executive Officer of the
Registrant. Mr. Silverman's background is as follows:
ANTHONY SILVERMAN, who formerly resigned as a member of our Board of
Directors on October 12, 2007, now will serve as Director, President and Chief
Executive Officer. He is the holder , and is the holder, together with his
affiliates, of 24,984,852 shares of our common stock. He is a private investor
in Scottsdale, Arizona investing in micro and small-cap public companies. Mr.
Silverman has been a shareholder of BestNet since April 2002. Mr. Silverman was
Founder, Chairman and CEO of Paradise Valley Securities from 1987 to 1999. For
most of his 30-year career in the securities business, Mr. Silverman
concentrated in transactions for the financing of micro-cap and small-cap
companies. Mr. Silverman has led financings aggregating over $500 million for
close to 100 companies, including diverse industries such as airlines, food
products, telecommunications, retail, media and life sciences.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: April 10, 2009 ONCOLOGIX TECH, INC.
By: /s/ Anthony Silverman
--------------------------------
Anthony Silverman,
President
By: /s/ Michael A. Kramarz
--------------------------------
Michael A. Kramarz,
Chief Financial Officer